*Titles, times, and locations may change. Check SABCS.org or the SABCS meeting platform and mobile app for the latest schedule.

GENERAL SESSION 3
Friday, December 8
8:15 a.m. – 11:30 a.m.
Hall 1

8:15–8:30 a.m. – GS03-01: Magnetic resonance imaging and a 12-Gene expression assay to optimize local therapy for ductal carcinoma in situ: 5-year clinical outcomes of E4112

8:30–8:45 a.m. – GS03-02: Mammographic surveillance in early breast cancer patients aged 50 years or over: Results of the Mammo-50 non-inferiority trial of annual versus less frequent mammography

8:45–9:00 a.m. – GS03-03: Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2− early breast cancer: final invasive disease–free survival (iDFS) analysis from the NATALEE trial

9:00–9:15 a.m. – GS03-04: Novel mechanisms of CDH1 inactivation in breast invasive lobular carcinoma unveiled by the integration of artificial intelligence and genomics

9:15–9:30 a.m. – GS03-05: Discussant for GS03-04

9:30–9:45 a.m. – GS03-06: Genomic and transcriptomic profiling of primary tumors from patients with HR+, HER2-, node-positive, high-risk early breast cancer in the monarchE trial

9:45–10:00 a.m. – GS03-07: Protocol-defined biomarker analysis in the PALLAS (AFT-05) adjuvant trial: Genomic subtype derived from RNA sequencing of HR+/HER2- early breast cancer

10:00–10:15 a.m. – GS03-08: Discussant for GS03-07

10:15–10:30 a.m. – GS03-09: Characterization and proposed therapeutic exploitation of fusion RNAs in metastatic breast cancers

10:30–10:45 a.m. – GS03-10: Allosteric PI3K-alpha inhibition overcomes on-target resistance to orthosteric inhibitors mediated by secondary PIK3CA mutations

10:45–11:00 a.m. – GS03-11: Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity

11:00–11:15 a.m. – GS03-12: Phase III study of adjuvant ado-trastuzumab emtansine vs trastuzumab for residual invasive HER2-positive early breast cancer after neoadjuvant chemotherapy and HER2-targeted therapy: KATHERINE final IDFS and updated OS analysis

11:15–11:30 a.m. – GS03-13: Phase III study of inavolisib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA-mutant, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: INAVO120 primary analysis

LATE-BREAKING ABSTRACTS ORAL SESSION
12:00 p.m. – 12:45 p.m.
Stars at Night Ballroom 1-2

LBO1-01: Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study

LBO1-02: Pathologic complete response (pCR) of neoadjuvant therapy with or without atezolizumab in HER2-positive, early high-risk and locally advanced breast cancer: APTneo Michelangelo randomized trial

LBO1-04: Primary results from a phase 2a study of zanidatamab (zani) + palbociclib (palbo) + fulvestrant (fulv) in HER2+/HR+ metastatic breast cancer (mBC)

LBO1-05: Impact of age and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): Results from the multicenter ADAPTcycle trial (n=4,334)

POSTER SPOTLIGHT SESSION #16: ENHANCING IMMUNOTHERAPY FOR TRIPLE NEGATIVE BREAST CANCER: NOVEL THERAPIES AND BIOMARKERS
7:00 a.m. – 8:00 a.m.
Stars at Night Ballroom 3-4

Presentations:

PS16-01: Comparison of an Atezolizumab monotherapy window followed by Atezolizumab and chemotherapy vs. Atezolizumab and chemotherapy alone in triple negative breast cancer (TNBC) – final analysis of the neoadjuvant neoMono trial

PS16-02: Efficacy and safety of first-line atezolizumab + bevacizumab + paclitaxel in patients with advanced triple-negative breast cancer: the ATRACTIB phase 2 trial.

PS16-03: Intratumoral dosing of INT230-6 in early-stage breast cancer patients induces tumor cell necrosis and immunomodulatory effects: A phase ii randomized window-of-opportunity study – the INVINCIBLE trial

PS16-04: Denosumab as an enhancer of the immune infiltrate in hormone receptor-positive early breast cancer. Subgroup analysis from the D-Biomark window-of-opportunity clinical trial (NCT03691311)

PS16-05: Discussant and panel discussion

PS16-06: Tumor-infiltrating lymphocytes and pathologic response to neoadjuvant chemotherapy with the addition of platinum and pembrolizumab in TNBC: A single-center real-world study

PS16-07: Tumor infiltrating lymphocyte stratification refines AJCC TNM staging based outcomes of early-stage triple negative breast cancer treated with neoadjuvant anthracycline-free, docetaxel and carboplatin chemotherapy

PS16-08: Histologic pattern and outcomes in high-grade metaplastic breast cancer compared to triple-negative ductal breast cancer counterparts: A single institution retrospective study

PS16-09: Analysis of the Radiosensitivity Index/Genomic-Adjusted Radiation Dose (RSI-GARD) in paired pre- and post-treatment TNBC samples: Implications for biomarker-guided radiotherapy

PS16-10: Spatial immune cell distribution can refine prognosis in early-stage ER+/HER2-/LN- breast cancer

PS16-11: Discussant and panel discussion

POSTER SPOTLIGHT SESSION #17: BIOMARKERS OF RESPONSE AND/OR RESISTANCE TO ENDOCRINE BASED THERAPIES: IMPLICATIONS FOR TREATMENT APPROACHES
7:00 a.m. – 8:00 a.m.
Hemisfair Ballroom 1-2

Presentations:

PS17-01: Key drivers of therapeutic response and resistance to giredestrant from GO39932: a Phase Ia/b study in patients with estrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer

PS17-02: Elacestrant vs standard-of-care in ER+/HER2- advanced or metastatic breast cancer (mBC) with ESR1 mutation: key biomarkers and clinical subgroup analyses from the phase 3 EMERALD trial

PS17-03: Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant HR positive/HER2-negative advanced breast cancer: exploratory analysis of PFS by AKT pathway gene from the Phase 3 CAPItello-291 trial

PS17-04: Clinical and Genomic Features of ER-Positive/HER2-negative Metastatic Breast Cancer in AURORA Molecular Screening Initiative (BIG 14-01): Mechanisms of Endocrine Therapy Resistance and Implications for Adjuvant Approaches

PS17-05: Discussant and panel discussion

PS17-06: A phase I trial of the PI3K inhibitor (PI3Ki) copanlisib and fulvestrant in combination with continuous or intermittent abemaciclib in patients with estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer

PS17-07: Interim analysis of giredestrant + inavolisib in MORPHEUS Breast Cancer: A Phase Ib/II study of giredestrant treatment combinations in estrogen receptor-positive, HER2-negative, locally advanced/metastatic breast cancer

PS17-08: A Phase Ib Study to evaluate the efficacy and safety of afuresertib plus fulvestrant in patients with locally advanced or metastatic HR+/HER2- breast cancer who failed standard of care therapies

PS17-09: An FGFR1/2 degrader overcomes antiestrogen resistance in ER+/FGFR1-amplified breast cancer

PS17-10: Discussant and panel discussion

POSTER SPOTLIGHT SESSION #18: DISPARATE CARE CALLS FOR DESPERATE MEASURES:  UNDERSTANDING GAPS IN QUALITY OF CARE AND OPPORTUNITIES TO IMPROVE IT
7:00 a.m. – 8:00 a.m.
Stars at Night Ballroom 1-2

Presentations:

PS18-01: Stage advancement and the rate of growth associated with preoperative delay in patients having breast cancer

PS18-02: Prevalence of refusal of recommended cancer treatments and survival differences in breast cancer patients: analysis of the national cancer database

PS18-03: The association between food deserts, food swamps, and postmenopausal breast cancer mortality in the United States

PS18-04: Racial disparities in breast cancer and effect of obesity: MammaPrint, BluePrint and whole transcriptome analyses of tumors in Latin American patients in FLEX trial

PS18-05: Discussant and panel discussion

PS18-07: Trends in guideline concordant care for inflammatory breast cancer: an analysis of the national cancer database

PS18-08: Bridging disparities in survivorship care: Leveraging telehealth for diverse patients in safety net hospital

PS18-09: The DARC side of breast cancer – DARC, Duffy-null and African ancestry influence in the Triple Negative Breast Cancer tumor microenvironment

PS18-10: Tumor-Infiltrating lymphocytes and breast cancer mortality in racially and ethnically diverse participants of the northern California breast cancer family registry

PS18-11: Discussant and panel discussion